Researcher Lends Clinical Expertise to Evaluate New Diagnostic Technologies and Support Science Research

Alameda, CA – July 7, 2020 – Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Professor Justin Stebbing M.D., Ph.D., has been appointed to its Scientific Advisory Board (SAB). In this role, Professor Stebbing will provide strategic direction on new technologies and support Alveo’s efforts in publishing the science and providing an objective scientific perspective about the company’s be.well™ platform, a point-of-care and at home diagnostic tool currently under development.

Professor Stebbing, an internationally recognized researcher in the field of oncology, brings more than a decade of clinical research experience to Alveo’s SAB. He is currently Professor of Cancer Medicine and Oncology and Consultant Oncologist at Imperial College London, specializing in new therapies in cancer, and he has recently begun spearheading broad international collaborations to advance COVID-19 research. He has published over 600 peer-reviewed papers in journals such as The Lancet, New England Journal, and The Journal of Clinical Oncology and is also Editor-in-Chief of Oncogene, a leading cancer journal. He is a Fellow of the Royal College of Physicians and the Royal College of Pathologists, and sits on the advisory boards of numerous international cancer committees. Stebbing holds a first class degree in medicine from Trinity College Oxford and a Ph.D. from Imperial College London.

“We are thrilled to welcome Justin to Alveo’s prestigious Scientific Advisory Board as his recent leadership on COVID-19 research has been critical to further our understanding of a new infectious disease,” said Ron Chiarello, Ph.D., Chairman, CEO and Founder of Alveo. “As we work to decentralize diagnostic testing with our be.well™ technology, we know Justin’s strong research background and deep scientific expertise will be a valuable asset to Alveo’s growth and we look forward to working with him to further validate and develop our be.well™ system.”

In addition to Professor Stebbing, Alveo’s SAB consists of leading experts and luminaries in the fields of diagnostics, genomics and biology. This team of leading experts are providing external expertise about the quality and robustness of the overall development program and thought leadership about cutting edge ideas that inform corporate and lifecycle strategy. Other SAB members include prominent leaders such as George Church, Ph.D., John DeVincenzo, M.D. and Pooja Goel.

“I am excited to be joining Alveo and am honored to have the opportunity to apply my knowledge to help them transform diagnostic testing across diseases from infections to cancer,” said Stebbing. “Alveo’s work in developing an affordable, easy-to-use, at-home diagnostic platform is at the forefront of the industry and has great potential to change the way diseases are detected and managed. I look forward to working closely with the Alveo team to execute their vision of making the promise of the be.well™ platform a reality.”

To learn more about Alveo’s Scientific Advisory Board, visit: https://www.alveotechnologies.com/about/.

About Alveo

Alveo is leading the transformation of the consumer health tech market with a low-cost, easy-to-use, at-home diagnostic platform that will change the way infectious diseases are detected and managed. The company’s be.well™ testing system gives individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections, including COVID-19, Influenza A/B and RSV, Alveo’s agile and dynamic diagnostic platform can be adapted to detect a wide range of diseases that threaten public health. Affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, we will know sooner, act faster and make better-informed decisions toward personalized intervention options that benefit individuals and the entire population. To learn more, visit https://www.alveotechnologies.com/

###

Media Contact:

Danielle Johns

Aria Marketing for Alveo

djohns@ariamarketing.com

845-304-7408

error: Content Restricted